Loading
Pharmaceutical
11 min read
Areas of Expertise :
Pharmaceutical, Pharmacology, Epidemiology, Oncology, Product Liability
Published Date:
Last Modified Date:
Jurisdiction:
California State
Cooper v. Takeda Pharmaceuticals America, Inc. is a California Court of Appeal decision involving claims that long-term use of Actos, the brand name for pioglitazone, contributed to Jack Cooper’s bladder cancer. The case addressed expert testimony in prescription drug litigation, including general causation, specific causation, epidemiology, and differential diagnosis. The appeal focused on whether the trial court properly excluded the plaintiffs’ medical causation evidence after a jury verdict. The appellate court reviewed accepted medical and scientific methods, expert admissibility standards, and the line between a judge’s gatekeeping role and the jury’s role in weighing competing evidence.
Actos, the brand name for pioglitazone, was approved by the U.S. Food and Drug Administration on July 15, 1999, for the treatment of Type 2 diabetes. The drug later became widely prescribed in the United States as part of diabetes management.
Over time, regulatory review, postmarketing safety information, and observational studies examined whether extended pioglitazone use might be associated with an increased risk of bladder cancer. Those scientific and regulatory questions became part of the factual background in Actos product liability and failure-to-warn litigation.
Jack Cooper began taking Actos in 2006 as part of his diabetes treatment. His treatment history later became part of the plaintiffs’ claims involving long-term exposure, warning adequacy, and whether Actos was a substantial contributing factor in his bladder cancer diagnosis.
The timing of Cooper’s Actos use was central to the causation dispute. The plaintiffs relied on expert testimony to connect Cooper’s individual medication history to the broader scientific evidence concerning pioglitazone and bladder cancer risk.
In June 2011, the FDA issued a Drug Safety Communication stating that use of pioglitazone for more than one year may be associated with an increased risk of bladder cancer. The communication advised healthcare providers to consider this potential risk when prescribing pioglitazone-containing medications.
In later Actos failure-to-warn litigation, the FDA communication provided regulatory context for drug safety, labeling updates, manufacturer knowledge, and the risk information available to prescribers and patients. It did not, by itself, prove medical causation in Cooper’s individual case.
In August 2011, the FDA approved updated labeling for pioglitazone-containing drugs. The revised warnings advised against use in patients with active bladder cancer and recommended caution in patients with a prior history of bladder cancer.
These labeling changes were part of the regulatory background for the plaintiffs’ failure-to-warn claims. The warning history helped frame what risk information was available, while the plaintiffs still needed admissible expert testimony to support general and specific causation.
In November 2011, Jack Cooper was diagnosed with bladder cancer after several years of Actos therapy. He and his wife, Nancy Cooper, later filed suit against Takeda Pharmaceuticals America, Inc. and related Takeda entities.
The plaintiffs alleged that Actos increased Cooper’s risk of bladder cancer and that Takeda failed to provide adequate warnings about that potential risk. The diagnosis became the central injury claim in the litigation.
Due to Cooper’s poor health, the trial court granted trial preference in October 2012. That ruling moved the case toward trial on an accelerated schedule.
The case then proceeded toward trial with disputed expert testimony on drug causation, medical causation, epidemiology, and warning adequacy. The plaintiffs needed to prove both that Actos was capable of causing bladder cancer and that it was a substantial contributing factor in Cooper’s cancer.
The case proceeded to a jury trial, which concluded in April 2013. During trial, the plaintiffs relied on expert testimony from Dr. Norm Smith, a urologic oncologist, and Dr. Alfred I. Neugut, an epidemiologist and oncologist, to address causation issues involving Actos exposure and bladder cancer risk.
On April 26, 2013, the jury returned a verdict in favor of the plaintiffs. The jury found Takeda liable on strict liability failure-to-warn and negligent failure-to-warn theories. It awarded $5 million in compensatory damages to Jack Cooper and $1.5 million in loss-of-consortium damages to Nancy Cooper.
After the verdict, the trial court struck Dr. Norm Smith’s specific causation testimony, finding that his opinions were speculative and lacked sufficient foundation. The court granted judgment notwithstanding the verdict and, in the alternative, ordered a new trial.
These post-trial rulings shifted the focus from the jury’s failure-to-warn findings to the admissibility of expert testimony on causation. The rulings also placed the trial court’s evaluation of scientific disagreement, differential diagnosis, and drug injury causation at the center of the appeal.
During the appeal, Jack Cooper died in July 2014. Nancy Cooper continued the action as successor-in-interest.
This development changed the procedural posture of the case, but it did not end the litigation. The appeal remained focused on whether the trial court properly excluded medical causation testimony and set aside the jury’s verdict.
The California Court of Appeal reversed the trial court’s post-trial rulings, concluding that the court exceeded its evidentiary gatekeeping role. The appellate court reviewed Dr. Norm Smith’s causation testimony and considered how his differential diagnosis analysis related to the broader general causation evidence, including testimony from Dr. Alfred I. Neugut regarding epidemiology and bladder cancer risk.
The appellate court explained that when an expert applies a recognized method, such as differential diagnosis, the trial court’s role is to assess methodological reliability, not to resolve scientific disagreements or choose between competing conclusions. The court also explained that a medical expert is not required to rule out every possible alternative cause when there is no evidence that those alternatives are plausible or meaningful in the individual case.
Because the expert testimony met admissibility standards, disputes about Actos exposure, bladder cancer risk, and individual causation were matters for the jury. The appellate court reversed the judgment notwithstanding the verdict and the conditional new-trial order, then remanded the case with directions to enter judgment based on the jury’s verdict.
Further review was later denied, leaving the California Court of Appeal’s ruling in place. The decision addressed expert admissibility, differential diagnosis, general causation, specific causation, and trial-court gatekeeping in pharmaceutical injury and prescription drug liability cases.
The ruling did not eliminate the need for reliable expert testimony in drug injury cases. Instead, it clarified that courts should not exclude expert opinions simply because the parties dispute how scientific evidence should be interpreted.
Court:
Superior Court of California, County of Los Angeles
Case Name:
Cooper v. Takeda Pharmaceuticals America, Inc.
Pharmaceutical Product Liability
FDA Regulation
Drug Labels
Drug Regulation
Safety Warnings
Drug Research
Medical Research
Bladder
Cooper v. Takeda Pharmaceuticals America, Inc. is a California Court of Appeal decision involving claims that long-term use of Actos, the brand name for pioglitazone, contributed to Jack Cooper’s bladder cancer. The case addressed expert testimony in prescription drug litigation, including general causation, specific causation, epidemiology, and differential diagnosis. The appeal focused on whether the trial court properly excluded the plaintiffs’ medical causation evidence after a jury verdict. The appellate court reviewed accepted medical and scientific methods, expert admissibility standards, and the line between a judge’s gatekeeping role and the jury’s role in weighing competing evidence.
Actos, the brand name for pioglitazone, was approved by the U.S. Food and Drug Administration on July 15, 1999, for the treatment of Type 2 diabetes. The drug later became widely prescribed in the United States as part of diabetes management.
Over time, regulatory review, postmarketing safety information, and observational studies examined whether extended pioglitazone use might be associated with an increased risk of bladder cancer. Those scientific and regulatory questions became part of the factual background in Actos product liability and failure-to-warn litigation.
Jack Cooper began taking Actos in 2006 as part of his diabetes treatment. His treatment history later became part of the plaintiffs’ claims involving long-term exposure, warning adequacy, and whether Actos was a substantial contributing factor in his bladder cancer diagnosis.
The timing of Cooper’s Actos use was central to the causation dispute. The plaintiffs relied on expert testimony to connect Cooper’s individual medication history to the broader scientific evidence concerning pioglitazone and bladder cancer risk.
In June 2011, the FDA issued a Drug Safety Communication stating that use of pioglitazone for more than one year may be associated with an increased risk of bladder cancer. The communication advised healthcare providers to consider this potential risk when prescribing pioglitazone-containing medications.
In later Actos failure-to-warn litigation, the FDA communication provided regulatory context for drug safety, labeling updates, manufacturer knowledge, and the risk information available to prescribers and patients. It did not, by itself, prove medical causation in Cooper’s individual case.
In August 2011, the FDA approved updated labeling for pioglitazone-containing drugs. The revised warnings advised against use in patients with active bladder cancer and recommended caution in patients with a prior history of bladder cancer.
These labeling changes were part of the regulatory background for the plaintiffs’ failure-to-warn claims. The warning history helped frame what risk information was available, while the plaintiffs still needed admissible expert testimony to support general and specific causation.
In November 2011, Jack Cooper was diagnosed with bladder cancer after several years of Actos therapy. He and his wife, Nancy Cooper, later filed suit against Takeda Pharmaceuticals America, Inc. and related Takeda entities.
The plaintiffs alleged that Actos increased Cooper’s risk of bladder cancer and that Takeda failed to provide adequate warnings about that potential risk. The diagnosis became the central injury claim in the litigation.
Due to Cooper’s poor health, the trial court granted trial preference in October 2012. That ruling moved the case toward trial on an accelerated schedule.
The case then proceeded toward trial with disputed expert testimony on drug causation, medical causation, epidemiology, and warning adequacy. The plaintiffs needed to prove both that Actos was capable of causing bladder cancer and that it was a substantial contributing factor in Cooper’s cancer.
The case proceeded to a jury trial, which concluded in April 2013. During trial, the plaintiffs relied on expert testimony from Dr. Norm Smith, a urologic oncologist, and Dr. Alfred I. Neugut, an epidemiologist and oncologist, to address causation issues involving Actos exposure and bladder cancer risk.
On April 26, 2013, the jury returned a verdict in favor of the plaintiffs. The jury found Takeda liable on strict liability failure-to-warn and negligent failure-to-warn theories. It awarded $5 million in compensatory damages to Jack Cooper and $1.5 million in loss-of-consortium damages to Nancy Cooper.
After the verdict, the trial court struck Dr. Norm Smith’s specific causation testimony, finding that his opinions were speculative and lacked sufficient foundation. The court granted judgment notwithstanding the verdict and, in the alternative, ordered a new trial.
These post-trial rulings shifted the focus from the jury’s failure-to-warn findings to the admissibility of expert testimony on causation. The rulings also placed the trial court’s evaluation of scientific disagreement, differential diagnosis, and drug injury causation at the center of the appeal.
During the appeal, Jack Cooper died in July 2014. Nancy Cooper continued the action as successor-in-interest.
This development changed the procedural posture of the case, but it did not end the litigation. The appeal remained focused on whether the trial court properly excluded medical causation testimony and set aside the jury’s verdict.
The California Court of Appeal reversed the trial court’s post-trial rulings, concluding that the court exceeded its evidentiary gatekeeping role. The appellate court reviewed Dr. Norm Smith’s causation testimony and considered how his differential diagnosis analysis related to the broader general causation evidence, including testimony from Dr. Alfred I. Neugut regarding epidemiology and bladder cancer risk.
The appellate court explained that when an expert applies a recognized method, such as differential diagnosis, the trial court’s role is to assess methodological reliability, not to resolve scientific disagreements or choose between competing conclusions. The court also explained that a medical expert is not required to rule out every possible alternative cause when there is no evidence that those alternatives are plausible or meaningful in the individual case.
Because the expert testimony met admissibility standards, disputes about Actos exposure, bladder cancer risk, and individual causation were matters for the jury. The appellate court reversed the judgment notwithstanding the verdict and the conditional new-trial order, then remanded the case with directions to enter judgment based on the jury’s verdict.
Further review was later denied, leaving the California Court of Appeal’s ruling in place. The decision addressed expert admissibility, differential diagnosis, general causation, specific causation, and trial-court gatekeeping in pharmaceutical injury and prescription drug liability cases.
The ruling did not eliminate the need for reliable expert testimony in drug injury cases. Instead, it clarified that courts should not exclude expert opinions simply because the parties dispute how scientific evidence should be interpreted.
Medical Causation Expert Witness: Urologic Oncology - Plaintiff
Dr. Norm Smith, a urologic oncologist, evaluated Cooper’s medical history and applied a differential diagnosis method to assess whether Actos was a substantial contributing factor in the development of bladder cancer. His role addressed specific causation because the case required expert testimony connecting Cooper’s individual diagnosis to his Actos exposure.
The trial court later excluded his specific causation opinions, but the California Court of Appeal reversed that ruling. The appellate court found that the trial court went too far by requiring Dr. Smith to rule out all possible alternative causes when there was no substantial evidence that those alternatives were meaningful in Cooper’s case.
General Causation Expert Witness: Epidemiology and Oncology - Plaintiff
Dr. Alfred I. Neugut, an epidemiologist and oncologist, evaluated epidemiological studies and scientific literature addressing whether pioglitazone was capable of increasing bladder cancer risk at the population level. His testimony supported the general causation component of the plaintiffs’ Actos-related injury claim.
This distinction mattered because prescription drug injury claims usually require proof of both general causation and specific causation. General causation asks whether the drug is capable of causing the alleged injury, while specific causation asks whether the drug contributed to the injury in the individual plaintiff.
Pharmacology and Drug Safety Expert Witness
Although the appellate opinion focused on Dr. Smith and Dr. Neugut, Actos bladder cancer litigation may also involve pharmacology and drug safety analysis involving exposure duration, dose-response questions, proposed biological mechanisms, and drug safety data.
Regulatory Affairs and FDA Compliance Expert Witness
Regulatory affairs analysis may be used in pharmaceutical failure-to-warn cases to examine FDA safety communications, labeling history, postmarketing surveillance, and manufacturer reporting obligations. This type of evidence may inform warning adequacy and manufacturer knowledge, but it does not replace the need for admissible medical and scientific testimony on causation.
Biostatistics Expert Witness
Biostatistics analysis may be relevant when parties dispute study design, statistical significance, confidence intervals, confounding variables, and the reliability of epidemiological evidence.
Expert Admissibility Depends on Reliable Methodology
Courts focus on whether expert opinions are grounded in reliable methods, such as differential diagnosis and epidemiological analysis. Cooper v. Takeda shows that expert testimony in prescription drug cases must connect medical reasoning, scientific literature, differential diagnosis, and the plaintiff’s facts in a reliable way.
Credentials alone are not enough. The opinion must be tied to a method the court can evaluate and the jury can weigh.
Courts Must Distinguish Methodology Problems from Scientific Disagreement
The decision distinguished between unreliable expert methodology and a dispute over how to interpret scientific evidence. The appellate court explained that when an expert uses a recognized method, disagreement with the expert’s conclusion may go to the weight of the testimony rather than admissibility.
That distinction can arise in pharmaceutical product liability cases where both sides present competing interpretations of epidemiology, clinical data, and patient-specific risk factors. A court may exclude unsupported speculation, but it should not replace the jury’s role by deciding which reasonable scientific interpretation is more persuasive.
General and Specific Causation Must Be Addressed Separately
Prescription drug injury claims require proof that a medication is capable of causing the alleged injury in general and that it contributed to the plaintiff’s injury in the specific case. The Cooper decision addressed both forms of causation in the context of Actos and bladder cancer claims.
Population-level risk evidence does not automatically prove individual causation. At the same time, patient-specific medical testimony usually depends on a reliable general causation foundation.
FDA Regulatory History Provides Context but Does Not Prove Causation
FDA safety communications and labeling changes may inform warning and manufacturer knowledge issues, but they do not substitute for admissible expert proof of medical causation. In Actos failure-to-warn litigation, regulatory history explained the changing safety record and labeling background.
The plaintiffs still needed expert testimony to address whether Actos was capable of causing bladder cancer and whether it contributed to Cooper’s cancer in particular.
Trial-Court Gatekeeping Has Limits
The decision addressed the boundary between judicial gatekeeping and the jury’s responsibility to weigh competing expert opinions in prescription drug liability litigation. Challenges to expert testimony are often directed at methodology, foundation, and relevance rather than the expert’s ultimate conclusion alone.
Cooper v. Takeda shows that a trial court may evaluate whether an expert used a reliable method. But when the expert’s method is recognized and supported by a sufficient foundation, disputes over competing conclusions are generally for the jury.
Cooper v. Takeda Pharmaceuticals America, Inc. followed a prescription drug product liability dispute from long-term Actos use and a bladder cancer diagnosis to a jury verdict, post-trial rulings, and appellate review. Jack and Nancy Cooper alleged that Takeda failed to adequately warn about bladder cancer risk associated with Actos. The litigation centered on whether expert testimony could support both general causation and specific causation. Although the jury found for the plaintiffs on failure-to-warn theories, the trial court later set aside the verdict after striking the plaintiffs’ medical causation evidence.
The California Court of Appeal reversed those post-trial rulings and directed entry of judgment based on the jury’s verdict. The decision addressed the admissibility of expert testimony, the use of differential diagnosis, and the boundary between judicial gatekeeping and the jury’s role in weighing competing scientific evidence. The case involved FDA labeling history, epidemiological evidence, and medical causation testimony, with postmarketing safety information forming part of the broader regulatory background.
What is Cooper v. Takeda Pharmaceuticals America, Inc. about?
Cooper v. Takeda Pharmaceuticals America, Inc. is a product-liability case involving claims that long-term use of Actos, the brand name for pioglitazone, caused Jack Cooper’s bladder cancer. Jack and Nancy Cooper alleged that Takeda failed to warn Jack’s treating physician adequately about the risk.
What did the California Court of Appeal decide in Cooper v. Takeda?
The California Court of Appeal reversed the judgment notwithstanding the verdict, the conditional new-trial order, and the subsequent judgment for Takeda. It determined that the trial court improperly struck Dr. Norm Smith’s specific-causation testimony by requiring him to rule out every other possible cause without substantial evidence that those causes were relevant. The case was remanded with directions to enter judgment based on the jury’s verdict.
What role did expert witnesses play in the case?
Dr. Alfred Neugut addressed epidemiological research and general causation, while Dr. Norm Smith used a differential-diagnosis method to assess the specific cause of Jack Cooper’s bladder cancer. The appellate court determined that Dr. Smith’s testimony was admissible and that questions concerning its weight were for the jury.
How did FDA labeling and safety communications affect the litigation?
FDA safety actions and Actos labeling provided regulatory context for the alleged bladder-cancer risk and Takeda’s warning obligations. They did not independently establish that Actos caused Jack Cooper’s cancer. The plaintiffs relied on medical and epidemiological testimony to establish general and specific causation.
What happened after the jury verdict in Cooper v. Takeda?
The jury found Takeda liable for strict-liability and negligent failure to warn and awarded $5 million to Jack Cooper and $1.5 million to Nancy Cooper for loss of consortium. The trial court later struck Dr. Smith’s causation testimony, granted judgment notwithstanding the verdict, and conditionally ordered a new trial. The Court of Appeal reversed those rulings and directed the trial court to enter a new judgment based on the verdict.
Medical Causation Expert Witness: Urologic Oncology - Plaintiff
Dr. Norm Smith, a urologic oncologist, evaluated Cooper’s medical history and applied a differential diagnosis method to assess whether Actos was a substantial contributing factor in the development of bladder cancer. His role addressed specific causation because the case required expert testimony connecting Cooper’s individual diagnosis to his Actos exposure.
The trial court later excluded his specific causation opinions, but the California Court of Appeal reversed that ruling. The appellate court found that the trial court went too far by requiring Dr. Smith to rule out all possible alternative causes when there was no substantial evidence that those alternatives were meaningful in Cooper’s case.
General Causation Expert Witness: Epidemiology and Oncology - Plaintiff
Dr. Alfred I. Neugut, an epidemiologist and oncologist, evaluated epidemiological studies and scientific literature addressing whether pioglitazone was capable of increasing bladder cancer risk at the population level. His testimony supported the general causation component of the plaintiffs’ Actos-related injury claim.
This distinction mattered because prescription drug injury claims usually require proof of both general causation and specific causation. General causation asks whether the drug is capable of causing the alleged injury, while specific causation asks whether the drug contributed to the injury in the individual plaintiff.
Pharmacology and Drug Safety Expert Witness
Although the appellate opinion focused on Dr. Smith and Dr. Neugut, Actos bladder cancer litigation may also involve pharmacology and drug safety analysis involving exposure duration, dose-response questions, proposed biological mechanisms, and drug safety data.
Regulatory Affairs and FDA Compliance Expert Witness
Regulatory affairs analysis may be used in pharmaceutical failure-to-warn cases to examine FDA safety communications, labeling history, postmarketing surveillance, and manufacturer reporting obligations. This type of evidence may inform warning adequacy and manufacturer knowledge, but it does not replace the need for admissible medical and scientific testimony on causation.
Biostatistics Expert Witness
Biostatistics analysis may be relevant when parties dispute study design, statistical significance, confidence intervals, confounding variables, and the reliability of epidemiological evidence.
Expert Admissibility Depends on Reliable Methodology
Courts focus on whether expert opinions are grounded in reliable methods, such as differential diagnosis and epidemiological analysis. Cooper v. Takeda shows that expert testimony in prescription drug cases must connect medical reasoning, scientific literature, differential diagnosis, and the plaintiff’s facts in a reliable way.
Credentials alone are not enough. The opinion must be tied to a method the court can evaluate and the jury can weigh.
Courts Must Distinguish Methodology Problems from Scientific Disagreement
The decision distinguished between unreliable expert methodology and a dispute over how to interpret scientific evidence. The appellate court explained that when an expert uses a recognized method, disagreement with the expert’s conclusion may go to the weight of the testimony rather than admissibility.
That distinction can arise in pharmaceutical product liability cases where both sides present competing interpretations of epidemiology, clinical data, and patient-specific risk factors. A court may exclude unsupported speculation, but it should not replace the jury’s role by deciding which reasonable scientific interpretation is more persuasive.
General and Specific Causation Must Be Addressed Separately
Prescription drug injury claims require proof that a medication is capable of causing the alleged injury in general and that it contributed to the plaintiff’s injury in the specific case. The Cooper decision addressed both forms of causation in the context of Actos and bladder cancer claims.
Population-level risk evidence does not automatically prove individual causation. At the same time, patient-specific medical testimony usually depends on a reliable general causation foundation.
FDA Regulatory History Provides Context but Does Not Prove Causation
FDA safety communications and labeling changes may inform warning and manufacturer knowledge issues, but they do not substitute for admissible expert proof of medical causation. In Actos failure-to-warn litigation, regulatory history explained the changing safety record and labeling background.
The plaintiffs still needed expert testimony to address whether Actos was capable of causing bladder cancer and whether it contributed to Cooper’s cancer in particular.
Trial-Court Gatekeeping Has Limits
The decision addressed the boundary between judicial gatekeeping and the jury’s responsibility to weigh competing expert opinions in prescription drug liability litigation. Challenges to expert testimony are often directed at methodology, foundation, and relevance rather than the expert’s ultimate conclusion alone.
Cooper v. Takeda shows that a trial court may evaluate whether an expert used a reliable method. But when the expert’s method is recognized and supported by a sufficient foundation, disputes over competing conclusions are generally for the jury.
Cooper v. Takeda Pharmaceuticals America, Inc. followed a prescription drug product liability dispute from long-term Actos use and a bladder cancer diagnosis to a jury verdict, post-trial rulings, and appellate review. Jack and Nancy Cooper alleged that Takeda failed to adequately warn about bladder cancer risk associated with Actos. The litigation centered on whether expert testimony could support both general causation and specific causation. Although the jury found for the plaintiffs on failure-to-warn theories, the trial court later set aside the verdict after striking the plaintiffs’ medical causation evidence.
The California Court of Appeal reversed those post-trial rulings and directed entry of judgment based on the jury’s verdict. The decision addressed the admissibility of expert testimony, the use of differential diagnosis, and the boundary between judicial gatekeeping and the jury’s role in weighing competing scientific evidence. The case involved FDA labeling history, epidemiological evidence, and medical causation testimony, with postmarketing safety information forming part of the broader regulatory background.
What is Cooper v. Takeda Pharmaceuticals America, Inc. about?
Cooper v. Takeda Pharmaceuticals America, Inc. is a product-liability case involving claims that long-term use of Actos, the brand name for pioglitazone, caused Jack Cooper’s bladder cancer. Jack and Nancy Cooper alleged that Takeda failed to warn Jack’s treating physician adequately about the risk.
What did the California Court of Appeal decide in Cooper v. Takeda?
The California Court of Appeal reversed the judgment notwithstanding the verdict, the conditional new-trial order, and the subsequent judgment for Takeda. It determined that the trial court improperly struck Dr. Norm Smith’s specific-causation testimony by requiring him to rule out every other possible cause without substantial evidence that those causes were relevant. The case was remanded with directions to enter judgment based on the jury’s verdict.
What role did expert witnesses play in the case?
Dr. Alfred Neugut addressed epidemiological research and general causation, while Dr. Norm Smith used a differential-diagnosis method to assess the specific cause of Jack Cooper’s bladder cancer. The appellate court determined that Dr. Smith’s testimony was admissible and that questions concerning its weight were for the jury.
How did FDA labeling and safety communications affect the litigation?
FDA safety actions and Actos labeling provided regulatory context for the alleged bladder-cancer risk and Takeda’s warning obligations. They did not independently establish that Actos caused Jack Cooper’s cancer. The plaintiffs relied on medical and epidemiological testimony to establish general and specific causation.
What happened after the jury verdict in Cooper v. Takeda?
The jury found Takeda liable for strict-liability and negligent failure to warn and awarded $5 million to Jack Cooper and $1.5 million to Nancy Cooper for loss of consortium. The trial court later struck Dr. Smith’s causation testimony, granted judgment notwithstanding the verdict, and conditionally ordered a new trial. The Court of Appeal reversed those rulings and directed the trial court to enter a new judgment based on the verdict.
Pharmaceutical Product Liability
FDA Regulation
Drug Labels
Drug Regulation
Safety Warnings
Drug Research
Medical Research
Bladder
Securities, +4
Pharmaceutical
Pharmaceutical, +4
Pharmaceutical